Stephanie Efthymiou,Cailyn Leo,Chenghong Deng,Kejia Zhang,Sheng-Jia Lin,Reza Maroofian,Rauan Kaiyrzhanov,Renee Qing Lin,Irem Karagoz,Annarita Scardamaglia,Daniel Owrang,Valentina Turchetti,Friederike Jahnke,Cassidy Petree,Anna V Derrick,Mark I Rees,Javeria Raza Alvi,Tipu Sultan,Chumei Li,Marie-Line Jacquemont,Frederic Tran-Mau-Them,Maria Irene Valenzuela Palafoll,Rich Sidlow,Grace Yoon,Michelle Morrow,Alexis Carere,Mary O'Connor,Julie Fleischer,Erica H. Gerkes,Chanika Phornphutkul,Bertrand Isidor,Clotilde Rivier-Ringenbach,Christophe Philippe,Semra Hiz Kurul,Didem Soydemir,Bulent Kara,Deniz Sunnetci-Akkoyunlu,Viktoria Bothe,Konrad Platzer,Dagmar Wieczorek,Margarete Koch-Hogrebe,Nils Rahner,Ann-Charlotte Thuresson,Hans Matsson,Carina Frykholm,Sevcan Tug Bozdogan,Atil Bisgin,Nicolas Chatron,Gaetan Lesca,Sara Cabet,Zeynep Tumer,Tina Duelund Hjortshoj,Gitte Ronde,Thorsten Marquardt,Janine Reunert,Erum Afzal,Mina Zamani,Reza Azizimalamiri,Hamid Galehdari,Pardis Nourbakhshd,Niloofar Chamanrou,Seo-Kyung Chung,Mohnish Suri,Paul J Benke,Maha S Zaki,Joseph G Gleeson,Daniel G Calame,Davut Pehlivan,Halil Ibrahim Yilmaz,Alper Gezdirici,Aboulfazl Rad,Iman Sabri Abumansour,Gabriela Oprea,Jai Sidpra,Kshitij Mankad,Barbara Vona,Andrew Fry,Gaurav K Varshney,Henry Houlden,Dragony Fu

Abstract:The post-transcriptional modification of tRNAs plays a key role in tRNA folding and function to ensure proper levels of protein synthesis during growth and development. Pathogenic variants in tRNA modification enzymes have been implicated in diverse human neurodevelopmental and neurological disorders. However, the molecular basis for many of these disorders remains unknown, thereby limiting our understanding and potential treatment of pathologies linked to tRNA modification. Here, we describe an extensive cohort of 31 individuals from 24 unrelated families with bi-allelic variants in the ( ) gene who present with a syndromic neurodevelopmental disorder universally characterized by intellectual disability in affected patients. Developmental delay, behavioral abnormalities and facial dysmorphisms represent additional core phenotypes of this syndrome. The variants include novel and ultra-rare TRMT1 variants that segregate with clinical pathology. We found that a subset of variants causes mis-splicing and loss of TRMT1 protein expression. Notably, patient cells with TRMT1 variants exhibit a deficiency in tRNA modifications catalyzed by TRMT1. Molecular analysis of TRMT1 variants reveal distinct regions of the TRMT1 protein required for tRNA modification activity and binding, including a TRMT1 subdomain critical for tRNA interaction. Importantly, depletion of TRMT1 in zebrafish is sufficient to induce developmental and behavioral phenotypes that recapitulate those observed in human patients with pathogenic TRMT1 variants. Altogether, these findings demonstrate that loss of TRMT1-catalyzed tRNA modifications leads to a syndromic form of intellectual disability and elucidate the molecular underpinnings of tRNA modification deficiency caused by pathogenic TRMT1 variants.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the molecular mechanisms of syndromic neurodevelopmental disorders caused by biallelic pathological variants in the TRMT1 gene. Specifically, the study focuses on the following points: 1. **Identification of pathological variants in the TRMT1 gene**: Through exome or genome sequencing, novel and ultra - rare biallelic variants in the TRMT1 gene of 31 individuals with neurodevelopmental disorders from 24 unrelated families were identified. 2. **Description of phenotypic characteristics**: The clinical phenotypes of these patients were described in detail, including intellectual disability, global developmental delay, facial dysmorphism, delay in motor milestones, seizures, abnormal muscle tone, coordination disorders, behavioral problems, etc. 3. **Effects of variants on TRMT1 protein expression and function**: The effects of these variants on the expression level and splicing pattern of TRMT1 protein were evaluated by experimental methods (such as immunoblotting, RT - PCR, Sanger sequencing, etc.). 4. **Molecular basis of tRNA modification defects**: The tRNA modification (especially N2, N2 - dimethylguanosine, m2,2G) defects caused by TRMT1 variants in patient cells were studied, and how these defects affect protein synthesis and cell proliferation was explored. 5. **Animal model verification**: By knocking down the TRMT1 gene in zebrafish, it was verified whether these variants would lead to similar developmental and behavioral phenotypes, thereby further supporting the findings in human patients. In summary, this paper aims to comprehensively analyze how TRMT1 gene variants lead to a series of neurodevelopmental disorders by affecting tRNA modification and provide a scientific basis for future diagnosis and treatment.

Biallelic pathogenic variants in TRMT1 disrupt tRNA modification and induce a syndromic neurodevelopmental disorder